Akari Therapeutics Plc
A biotech company engineering antibody-drug conjugates—"smart bombs" that carry a toxin to cancer cells. Its twist is a payload called PH1 that disrupts how cancer cells splice their RNA, killing them and waking the immune system; its lead drug AKTX-101 targets the TROP2 protein on solid tumors. Akari was born in 2015 when Celsus Therapeutics absorbed Volution Immuno Pharmaceuticals and took a name meaning "light" in Japanese. Earlier it made Coversin, a drug derived from tick saliva.
Sponsored ADR
Granted 892.9K
Granted 479.57M
Granted 44.6K
Granted 158.47M
Granted 3.26B
Granted 1.75B
Granted 71.93M · Bought 52.1K
Granted 44.6K
Granted 10.00M
Granted 83.7K
Granted 200
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Huh HoyoungDirector, 10% owner · 1 transaction | — | 7.62Bas of Mar 2025 | 892.9K | — | — |
| Jacques Rachelle SuzanneChief Executive Officer, Director · 1 transaction | — | 1.02Bas of Apr 2024 | 479.57M | — | — |
| Patel Sandip IDirector · 1 transaction | — | 984.81Mas of Apr 2025 | 44.6K | — | — |
| Dicicco Wendy FInterim CFO · 1 transaction | — | 158.47Mas of May 2024 | 158.47M | — | — |
| Patel Samir RashmikantDirector · 11 transactions | — | 6.15Mas of Mar 2025 | 3.26B | — | — |
| Prudo-Chlebosz RaymondDirector · 3 transactions | — | 5.41Mas of Mar 2025 | 1.75B | — | — |
| Gaslightwala AbizerCEO, Director · 15 transactions | — | 298.6Kas of Aug 2025 | 71.93M | 52.1K | — |
| Bazemore Robert BDirector · 1 transaction | — | 44.6Kas of Mar 2025 | 44.6K | — | — |
| Neal James RDirector · 3 transactions | — | 36.3Kas of Mar 2025 | 10.00M | — | — |
| Farag Kameel D.Interim CFO · 10 transactions | — | 2.9K | 83.7K | — | — |
| Hombeck TorstenCFO · 1 transaction | — | 200as of Mar 2025 | 200 | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: +52.1K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.